Explore more publications!
Health & Wellness Today New York
Submit Press Release

Health & Wellness Today New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 3, 2025

CC: The Booklet — Exposing Coercive Control and Empowering Survivors Through Knowledge
November 3, 2025

CC: The Booklet — Exposing Coercive Control and Empowering Survivors Through Knowledge

Indeterminate EIN Presswire
Solo Health Collective Partners with Catalant to Expand Affordable Health Coverage to Independent Experts
November 3, 2025

Solo Health Collective Partners with Catalant to Expand Affordable Health Coverage to Independent Experts

Indeterminate EIN Presswire
Naveck Technologies Empowers Startups and SMEs with Custom Software Development Solutions
November 3, 2025

Naveck Technologies Empowers Startups and SMEs with Custom Software Development Solutions

Indeterminate EIN Presswire
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 3, 2025

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Indeterminate GlobeNewswire
FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease
November 3, 2025

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease

Indeterminate GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Flo Health and Dr. Sameena Rahman Address Perimenopause and Its Workplace Impact with YourUpdateTV
November 3, 2025

Flo Health and Dr. Sameena Rahman Address Perimenopause and Its Workplace Impact with YourUpdateTV

Indeterminate GlobeNewswire
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
November 3, 2025

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Indeterminate GlobeNewswire
Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
November 3, 2025

Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results

Indeterminate GlobeNewswire
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
November 3, 2025

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Indeterminate GlobeNewswire
DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial
November 3, 2025

DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial

Indeterminate GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
November 3, 2025

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

Indeterminate GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
November 3, 2025

Olema Oncology to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
November 3, 2025

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025

Indeterminate GlobeNewswire
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2025
November 3, 2025

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2025

Indeterminate GlobeNewswire
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
November 3, 2025

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

Indeterminate GlobeNewswire
NANOBIOTIX participera à des conférences investisseurs la semaine du 10 novembre
November 3, 2025

NANOBIOTIX participera à des conférences investisseurs la semaine du 10 novembre

Indeterminate GlobeNewswire
Beta Bionics Announces Participation at Upcoming Investor Conferences
November 3, 2025

Beta Bionics Announces Participation at Upcoming Investor Conferences

Indeterminate GlobeNewswire
The Ensign Group Reports Third Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance
November 3, 2025

The Ensign Group Reports Third Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions